Bayer recalls Kogenate lots in Spain after out of spec stability results

By Gareth Macdonald

- Last updated on GMT

Bayer recalls Kogenate lots in Spain after out of spec stability results
Bayer has recalled its injectable haemophilia drug Kogenate in Spain according to the country’s regulators.

Details of the recall were made public by the Spanish Agency of Medicines and Medical Devices (AEMPS) late last week (here in Spanish​).

The Madrid-based regulatory organisation said the Kogenate recall was prompted by the detection of out of specification results during stability studies.

This was confirmed by Bayer spokesman Kilian Guasch Tellez who told us: "During routine product testing, stability data for specific lots of Kogenate FS/Bayer indicated that the product’s potency was declining during its shelf life at a greater pace than normal.

"As patient safety is our highest priority we are voluntarily recalling lots below potency specification and lots that currently meet the potency requirements but have been identified as being at risk of falling below specification prior to shelf life expiry.

He added that: "Based on data that have been reviewed so far for Kogenate FS/Bayer, no safety observations or signals have been detected by Bayer’s drug safety group which would be indicative of a low potency type product issue.

"We are working closely with regulatory authorities to ensure an efficient recall process that minimizes any disruption to supply and inconvenience to patients​."

Kogenate is a recombinant factor VIII (rFVIII), which is a blood-clotting recombinant protein that is an alternative to Factor VIII derived from donated plasma. It is used for the prophylactic treatment of haemophilia.

The affected Kogenate lots were made at Bayer's production plant in Berkley, US. 

In 2015​, Bayer announced it would create a $100m (€94m) product testing suite at the facility.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more